Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
The company, which is part of Opko Health's BioReference Laboratories, recently hired a new managing director, who plans to expand the firm's market and testing portfolio.
Experts at CAP16 said most practicing pathologists operate within specialties and rarely cross the divide into other test disciplines, which thwarts optimal patient care.
The revenue surge was largely due to revenues from Bio-Reference Laboratories, which Opko acquired in August 2015.
The company's revenues benefitted from the acquisition of Bio-Reference Laboratories this summer, which helped push up diagnostic services revenues.
Following the close of the deal, Opko's diagnostic services will be merged with Bio-Reference's operations.
The contracts with Stratose, Three Rivers Provider Network, and Fortified Provider Network provide coverage for Opko's testing services.
The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firm said that revenues per patient were up 3 percent, while the number of patients served grew 8 percent.
Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.